60 Degrees Pharmaceuticals, Inc. (SXTPW) shareholders
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
5
0 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $30.09K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Knight Therapeutics Inc. | 658,629 | 19.85% | 13G (passive) | Jul 22, 2026 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 476,866 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Daniel B. Asher Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital LLC (9.99%) | 372,429 | 9.99% | 13G (passive) | Jul 15, 2025 |
| Orca Capital AG | 320,000 | 9.90% | 13G (passive) | Jul 15, 2025 |
| Intracoastal Capital LLC Joint filing with Mitchell P. Kopin (9.10%), Daniel B. Asher (9.10%) | 263,158 | 9.10% | 13G (passive) amendment | Mar 31, 2026 |
| Heights Capital Management, Inc. Joint filing with CVI Investments, Inc. (7.00%) | 197,911 | 7.00% | 13G (passive) amendment | Mar 31, 2026 |
| Lind Global Partners III LLC Joint filing with Lind Global Fund III LP (5.45%), Easton Jeff (5.45%) | 191,571 | 5.45% | 13G (passive) | Jul 31, 2026 |
| Ayrton Capital LLC Joint filing with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (9.99%), Waqas Khatri (9.99%) | 163,480 | 9.99% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SXTPW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Walleye Capital LLC | 200,481 | – | $6.06K | – | 0.00% |
| Clear Street Group Inc. | 145,969 | – | $4.41K | – | 0.00% |
| Torno Capital, LLC | 47,169 | – | $1.43K | −47,169 | 0.00% |
| Susquehanna International Group, Llp | 10,892 | – | $329 | −7,271 | 0.00% |
| UBS Group AG | 647 | – | $20 | −55 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 5 | 0M | 0 / 0 | 3 / 3 | 0M | 0M |
| Q1 2026 | 8 | 1M | 0 / 2 | 5 / 0 | 0M | 0M |
| Q4 2025 | 8 | 1M | 1 / 7 | 0 / 1 | 0M | 0M |
| Q3 2025 | 8 | 0M | 4 / 1 | 1 / 0 | 0M | 0M |
| Q2 2025 | 5 | 0M | 1 / 1 | 2 / 2 | 0M | 0M |
| Q1 2025 | 6 | 0M | 1 / 0 | 3 / 2 | 0M | 0M |
| Q4 2024 | 7 | 0M | 0 / 7 | 0 / 1 | 0M | 0M |
| Q3 2024 | 8 | 0M | 1 / 1 | 2 / 1 | 0M | 0M |
| Q2 2024 | 8 | 0M | 1 / 7 | 0 / 1 | 0M | 0M |
| Q1 2024 | 8 | 0M | 1 / 1 | 1 / 2 | 0M | 0M |
| Q4 2023 | 9 | 0M | 1 / 0 | 2 / 0 | 0M | 0M |
| Q3 2023 | 8 | 0M | 8 / 0 | 0 / 0 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Geoffrey S. Dow | President and CEO, Director | 35,250 | Jun 15, 2026 |
| Kristen Landon | Chief Operating Officer | 4,540 | Aug 14, 2025 |
| Tyrone Miller | CFO | 26,370 | Jan 24, 2025 |
| Eric Francois | Director | – | May 19, 2026 |
| Cheryl Xu | Director | 13,816 | Jun 5, 2025 |
| Therapeutics Inc Knight | 10% owner | 1,766,966 | Jul 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Geoffrey S. Dow President and CEO, Director | Jun 12, 2026 | Buy | +7,350 | $1.38 | $10.14K | 24,131 |
| Geoffrey S. Dow President and CEO, Director | Dec 15, 2025 | Buy | +9,670 | $0.80 | $7.74K | 59,618 |
| Geoffrey S. Dow President and CEO, Director | Dec 11, 2025 | Buy | +3,613 | $0.92 | $3.32K | 49,948 |
| Geoffrey S. Dow President and CEO, Director | Dec 10, 2025 | Buy | +9,350 | $0.95 | $8.88K | 46,335 |
| Geoffrey S. Dow President and CEO, Director | Sep 12, 2025 | Award | +7,201 | $1.39 | $10.01K | 33,372 |
| Geoffrey S. Dow President and CEO, Director | Jun 9, 2025 | Award | +4,376 | $2.99 | $13.08K | 26,171 |
| Cheryl Xu Director | Jun 3, 2025 | Buy | +3,000 | $2.87 | $8.61K | 13,816 |
| Cheryl Xu Director | Jun 3, 2025 | Buy | +2,000 | $2.90 | $5.80K | 15,816 |
| Kristen Landon Chief Operating Officer | Jan 17, 2025 | Award | +4,540 | – | – | 4,540 |
| Tyrone Miller CFO | Jan 17, 2025 | Award | +11,626 | – | – | 26,370 |
| Geoffrey S. Dow President and CEO, Director | Jan 17, 2025 | Award | +14,394 | – | – | 108,974 |
| Cheryl Xu Director | Dec 16, 2024 | Buy | +2,000 | $1.45 | $2.90K | 54,078 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.60 | $2.40K | 47,578 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.58 | $2.37K | 49,078 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.55 | $2.33K | 50,578 |
| Cheryl Xu Director | Dec 13, 2024 | Buy | +1,500 | $1.52 | $2.28K | 52,078 |
| Cheryl Xu Director | Dec 12, 2024 | Buy | +2,500 | $1.80 | $4.50K | 46,078 |
| Cheryl Xu Director | Dec 12, 2024 | Buy | +2,500 | $1.85 | $4.63K | 43,578 |
| Geoffrey S. Dow President and CEO, Director | Dec 9, 2024 | Buy | +35,823 | $1.27 | $45.50K | 94,580 |
| Geoffrey S. Dow President and CEO, Director | Dec 6, 2024 | Buy | +20,579 | $1.20 | $24.69K | 58,757 |
| Geoffrey S. Dow President and CEO, Director | Dec 5, 2024 | Buy | +17,549 | $1.11 | $19.48K | 38,178 |
| Geoffrey S. Dow President and CEO, Director | Nov 21, 2024 | Buy | +3,500 | $0.91 | $3.19K | 20,629 |
| Geoffrey S. Dow President and CEO, Director | Nov 20, 2024 | Buy | +1,000 | $0.92 | $920 | 17,129 |
| Geoffrey S. Dow President and CEO, Director | Nov 19, 2024 | Buy | +2,500 | $0.90 | $2.25K | 16,129 |
| Cheryl Xu Director | Aug 27, 2024 | Buy | +5,000 | $1.70 | $8.50K | 41,078 |
| Stephen Toovey Director | May 16, 2024 | Award | +4,000 | $0.22 | $880 | 14,000 |
| Geoffrey S. Dow President and CEO, Director | May 16, 2024 | Option exercise | +17,000 | $0.22 | $3.74K | 762,625 |
| Charles W. Allen Director | May 16, 2024 | Option exercise | +4,000 | $0.22 | $880 | 14,000 |
| Paul Field Director | May 16, 2024 | Option exercise | +4,000 | $0.22 | $880 | 14,000 |
| Cheryl Xu Director | May 16, 2024 | Option exercise | +2,000 | $0.22 | $440 | 228,934 |
| Tyrone Miller CFO | May 16, 2024 | Award | +15,000 | $0.22 | $3.30K | 176,928 |
| Geoffrey S. Dow President and CEO, Director | Apr 12, 2024 | Option exercise | +68,000 | $0.27 | $18.36K | 745,625 |
| Tyrone Miller CFO | Apr 12, 2024 | Award | +60,000 | $0.27 | $16.20K | 161,928 |
| Cheryl Xu Director | Feb 1, 2024 | Option exercise | +2,000 | – | – | 6,000 |
| Geoffrey S. Dow President and CEO, Director | Jan 31, 2024 | Buy | +25,974 | $0.38 | $9.87K | 703,599 |
| Cheryl Xu Director | Jan 31, 2024 | Buy | +200,000 | $0.38 | $76.00K | 424,934 |
| Therapeutics International Sa Knight – | Jul 28, 2023 | Conversion | +45,560 | $4.75 | $216.41K | 1,153,897 |
| Therapeutics International Sa Knight – | Jul 28, 2023 | Conversion | −2,162 | – | – | 78,803 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+0.5%
From 0M shares
Short volume, 20 days
67.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of 60 Degrees Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,093 shares on Aug 25, 2026 over the last 90 days.